#United States #Montreal #FarmaMondo #Zemcelpro #ExCellThera

ExCellThera Announces Global Distribution Agreement for Zemcelpro®

On July 16, 2026, ExCellThera Inc., a leading company in blood stem cell expansion and metabolic fitness technologies, announced an important distribution partnership with FarmaMondo SA. This agreement grants FarmaMondo distribution rights for Zemcelpro® (also known as Dorocubicel or UM171 cell therapy) in key markets, including Argentina, Hong Kong, and Singapore.

Zemcelpro® is a pioneering cryopreserved product aimed at hematopoietic stem cell transplantation. It uniquely comprises two cellular components: expanded CD34+ cells with UM171 and non-expanded CD34- cells, both derived from the same umbilical cord blood unit. The European Commission has conditionally approved Zemcelpro® for treating adult patients with hematological malignancies who require allogeneic stem cell transplantation following myeloablative conditioning, particularly when no suitable donor is available.

FarmaMondo will leverage its expertise in regulatory affairs, market access, and specialty distribution to facilitate early access programs for Zemcelpro® in the designated territories. This alliance represents a significant advancement in Cordex Biologics' global marketing strategy for Zemcelpro®.

David Millette, CEO of Cordex, expressed that this partnership is a crucial step in ensuring access to vital therapies for patients with significant unmet medical needs. He emphasized the rising interest from healthcare providers, transplant centers, and commercial partners, reflecting an ongoing demand for innovative therapies addressing the persistent needs in blood cancers and stem cell transplantation.

Goals for the Agreement
The partnership with FarmaMondo aims to ensure patients can access Zemcelpro® through the relevant early access programs governing the regions involved. This move correlates with Cordex's ongoing strategies to enhance global access to Zemcelpro® and establish strategic partnerships. By promoting such access, the company reaffirms its commitment to addressing critical medical requirements in hematological conditions and facilitating patient care effectively.

Yaron Spigel, CEO of FarmaMondo, highlighted their enthusiastic partnership with Cordex, focusing on expanding access to Zemcelpro® in complex markets. The collaboration aligns with FarmaMondo’s mission to provide eligible patients in regions with limited drug accessibility the opportunity to receive innovative, specialized, and potentially lifesaving medications.

Background on Zemcelpro®
Zemcelpro® has received conditional market authorization from the European Commission for treating adults with hematological malignancies requiring stem cell transplantation when no suitable donor cells are available. Extensive clinical studies, involving over 120 patients in the US, Europe, and Canada, have shown promising results. The therapy has also been recognized with Orphan Drug status and designations highlighting its priority in regenerative medicine.

The drug is under review for regulatory submissions in several other regions, including the United States, Canada, the United Kingdom, and Switzerland. As part of ongoing research, Zemcelpro® is being studied for its efficacy among pediatric patients and those with non-malignant hematological diseases.

For more information about Zemcelpro®, visit zemcelpro.com.

About ExCellThera and the UM171 Technology
ExCellThera has established itself as a global leader in optimized blood stem cell therapies. Their Enhance™ platform is designed to generate a higher dose of functional therapeutic stem cells while minimizing the stress that may arise from cultivation or genetic manipulation. The company collaborates with biopharmaceutical firms to advance cutting-edge cell and gene therapies.

In conclusion, the partnership between ExCellThera and FarmaMondo marks a significant milestone in enhancing patient access to innovative therapies in Argentina, Hong Kong, and Singapore. It also contributes to the broader goal of addressing critical healthcare needs in different regions globally.